Emmes, a global Clinical Research Organization (CRO) that’s passionate about advancing public health and biopharmaceutical innovation, has made a major move with the acquisition of Essex Management. Essex is a premier provider of bioinformatics and health information technology (HIT) consulting services to government, private sector, and academic organizations.
This acquisition is a crucial step for Emmes in its mission to provide clients with innovative solutions and expand its services. By adding the expertise of Essex, Emmes will now be able to explore uncharted territories with government agencies and provide cutting-edge data strategies for biopharma clients.
The merger of Emmes and Essex will result in a clinical research powerhouse that’s unrivaled in the industry. With the combined strength of Emmes’ advanced analytics solutions and Essex’s technology skills, the CRO will be better equipped to tackle global health challenges and revolutionize the way clinical research is done.
Essex’s reputation as a technology catalyst in the life sciences, coupled with Emmes’ successful partnerships with the National Cancer Institute (NCI) and other public sector clients, will ignite a spark that will drive growth and propel clinical research to new heights.
